BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38367548)

  • 1. ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C.
    Lei ZN; Albadari N; Teng QX; Rahman H; Wang JQ; Wu Z; Ma D; Ambudkar SV; Wurpel JND; Pan Y; Li W; Chen ZS
    Drug Resist Updat; 2024 Mar; 73():101065. PubMed ID: 38367548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.
    Zhang L; Li Y; Hu C; Chen Y; Chen Z; Chen ZS; Zhang JY; Fang S
    Mol Cancer; 2022 Apr; 21(1):103. PubMed ID: 35459184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
    Wang J; Yang DH; Yang Y; Wang JQ; Cai CY; Lei ZN; Teng QX; Wu ZX; Zhao L; Chen ZS
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer.
    Yuan ZT; Shi XJ; Yuan YX; Qiu YY; Zou Y; Liu C; Yu H; He X; Xu K; Yin PH
    Oncotarget; 2017 Jul; 8(29):48012-48026. PubMed ID: 28624793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.
    Wang F; Li D; Zheng Z; Kin Wah To K; Chen Z; Zhong M; Su X; Chen L; Fu L
    J Exp Clin Cancer Res; 2020 Mar; 39(1):50. PubMed ID: 32164732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jatrophane diterpenes and cancer multidrug resistance - ABCB1 efflux modulation and selective cell death induction.
    Reis MA; Ahmed OB; Spengler G; Molnár J; Lage H; Ferreira MJ
    Phytomedicine; 2016 Aug; 23(9):968-78. PubMed ID: 27387405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor-
    Wang W; Zhang B; Mani AM; Wu Z; Fan Y; Li W; Wu ZH
    J Pharmacol Exp Ther; 2018 Jul; 366(1):184-193. PubMed ID: 29735611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
    Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
    Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells.
    Lin IL; Lin YT; Chang YC; Kondapuram SK; Lin KH; Chen PC; Kuo CY; Coumar MS; Cheung CHA
    Toxicol Appl Pharmacol; 2024 Apr; 485():116888. PubMed ID: 38452945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells.
    Abdelhafiz AHA; Serya RAT; Lasheen DS; Wang N; Sobeh M; Wink M; Abouzid KAM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2710-2724. PubMed ID: 36168121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Potent ABCB1 Modulator, Phenethylisoquinoline Alkaloid, Reverses Multidrug Resistance in Cancer Cell.
    Sugisawa N; Ohnuma S; Ueda H; Murakami M; Sugiyama K; Ohsawa K; Kano K; Tokuyama H; Doi T; Aoki J; Ishida M; Kudoh K; Naitoh T; Ambudkar SV; Unno M
    Mol Pharm; 2018 Sep; 15(9):4021-4030. PubMed ID: 30052463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of ABCB1 by collateral sensitivity drugs reverses multidrug resistance and up-regulates enolase I.
    Limniatis G; Georges E
    J Biochem; 2022 Jun; 172(1):37-48. PubMed ID: 35471238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
    Chong KY; Hsu CJ; Hung TH; Hu HS; Huang TT; Wang TH; Wang C; Chen CM; Choo KB; Tseng CP
    Cancer Biol Ther; 2015; 16(1):149-59. PubMed ID: 25590413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.
    Hui RC; Francis RE; Guest SK; Costa JR; Gomes AR; Myatt SS; Brosens JJ; Lam EW
    Mol Cancer Ther; 2008 Mar; 7(3):670-8. PubMed ID: 18347152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential oils from Inula japonica and Angelicae dahuricae enhance sensitivity of MCF-7/ADR breast cancer cells to doxorubicin via multiple mechanisms.
    Wu M; Li T; Chen L; Peng S; Liao W; Bai R; Zhao X; Yang H; Wu C; Zeng H; Liu Y
    J Ethnopharmacol; 2016 Mar; 180():18-27. PubMed ID: 26795076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
    Heffeter P; Jakupec MA; Körner W; Chiba P; Pirker C; Dornetshuber R; Elbling L; Sutterlüty H; Micksche M; Keppler BK; Berger W
    Biochem Pharmacol; 2007 Jun; 73(12):1873-86. PubMed ID: 17445775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.